
Issa J Dahabreh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3456423/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estimating Subgroup Effects in Generalizability and Transportability Analyses. American Journal of Epidemiology, 2024, 193, 149-158.	3.4	4
2	Efficient and Robust Methods for Causally Interpretable Meta-Analysis: Transporting Inferences from Multiple Randomized Trials to a Target Population. Biometrics, 2023, 79, 1057-1072.	1.4	6
3	Causal interaction trees: Finding subgroups with heterogeneous treatment effects in observational data. Biometrics, 2022, 78, 624-635.	1.4	7
4	Causally Interpretable Meta-analysis: Application in Adolescent HIV Prevention. Prevention Science, 2022, 23, 403-414.	2.6	10
5	Using Numerical Methods to Design Simulations: Revisiting the Balancing Intercept. American Journal of Epidemiology, 2022, 191, 1283-1289.	3.4	3
6	Predicting counterfactual risks under hypothetical treatment strategies: an application to HIV. European Journal of Epidemiology, 2022, , 1.	5.7	7
7	RE: Using numerical methods to design simulations: revisiting the balancing intercept. American Journal of Epidemiology, 2022, , .	3.4	0
8	Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration. American Journal of Epidemiology, 2022, 191, 1652-1665.	3.4	10
9	Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population. American Journal of Epidemiology, 2021, 190, 1632-1642.	3.4	35
10	Assessing Heterogeneity of Treatment Effects in Observational Studies. American Journal of Epidemiology, 2021, 190, 1088-1100.	3.4	11
11	Adjuvanted Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results From a Pragmatic Cluster-Randomized Clinical Trial. Clinical Infectious Diseases, 2021, 73, e4229-e4236.	5.8	8
12	Populationâ€level changes in outcomes and Medicare cost following the introduction of new cancer therapies. Health Services Research, 2021, 56, 486-496.	2.0	3
13	Comparing Effect Estimates in Randomized Trials and Observational Studies From the Same Population: An Application to Percutaneous Coronary Intervention. Journal of the American Heart Association, 2021, 10, e020357.	3.7	14
14	Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations. Epidemiology, 2020, 31, 614-619.	2.7	30
15	The Effect of Prenatal Treatments on Offspring Events in the Presence of Competing Events. Epidemiology, 2020, 31, 636-643.	2.7	20
16	Benchmarking Observational Analyses Against Randomized Trials: a Review of Studies Assessing Propensity Score Methods. Journal of General Internal Medicine, 2020, 35, 1396-1404.	2.6	21
17	Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens. JAMA Network Open, 2020, 3, e200452.	5.9	49
18	Realâ€world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer. Cancer, 2020, 126, 978-985.	4.1	52

Issa J Dahabreh

#	Article	IF	CITATIONS
19	Extending inferences from a randomized trial to a new target population. Statistics in Medicine, 2020, 39, 1999-2014.	1.6	94
20	Toward Causally Interpretable Meta-analysis. Epidemiology, 2020, 31, 334-344.	2.7	41
21	Contacting authors by telephone increased response proportions compared with emailing: results of a randomized study. Journal of Clinical Epidemiology, 2019, 115, 150-159.	5.0	12
22	Extending inferences from a randomized trial to a target population. European Journal of Epidemiology, 2019, 34, 719-722.	5.7	71
23	Generalizing Causal Inferences from Individuals in Randomized Trials to All Trial-Eligible Individuals. Biometrics, 2019, 75, 685-694.	1.4	86
24	Elimination of Cost Sharing for Screening Mammography in Medicare Advantage Plans. New England Journal of Medicine, 2018, 378, 262-269.	27.0	27
25	Propensity Score–Based Methods in Comparative Effectiveness Research on Coronary Artery Disease. American Journal of Epidemiology, 2018, 187, 1064-1078.	3.4	6
26	Randomization, randomized trials, and analyses using observational data: A commentary on Deaton and Cartwright. Social Science and Medicine, 2018, 210, 41-44.	3.8	4
27	Using observational data for personalized medicine when clinical trial evidence is limited. Fertility and Sterility, 2018, 109, 946-951.	1.0	15
28	Univariate and bivariate likelihood-based meta-analysis methods performed comparably when marginal sensitivity and specificity were the targets of inference. Journal of Clinical Epidemiology, 2017, 83, 8-17.	5.0	5
29	Validation and calibration of structural models that combine information from multiple sources. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 27-37.	1.4	1
30	<i>Open<scp>MEE</scp></i> : Intuitive, openâ€source software for metaâ€analysis in ecology and evolutionary biology. Methods in Ecology and Evolution, 2017, 8, 941-947.	5.2	267
31	Abstract 73: Risk of Paradoxical Embolism (RoPE) Score Stratification of Pooled Pfo Closure Clinical Trial Data: Lack of Evidence for Improvement in Patient Selection for Closure. Stroke, 2017, 48, .	2.0	0
32	Nuclear Imaging for Classic Fever of Unknown Origin: Meta-Analysis. Journal of Nuclear Medicine, 2016, 57, 1913-1919.	5.0	74
33	Recommendations for the Conduct and Reporting of Modeling and Simulation Studies in Health Technology Assessment. Annals of Internal Medicine, 2016, 165, 575.	3.9	12
34	Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. International Journal of Epidemiology, 2016, 45, dyw125.	1.9	66
35	Device Closure of Patent Foramen Ovale After Stroke. Journal of the American College of Cardiology, 2016, 67, 907-917.	2.8	183
36	Oral Mechanical Bowel Preparation for Colorectal Surgery. Diseases of the Colon and Rectum, 2015, 58, 698-707.	1.3	80

Issa J Dahabreh

#	Article	IF	CITATIONS
37	Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. European Heart Journal, 2015, 36, 2381-2389.	2.2	98
38	Using data sources beyond PubMed has a modest impact on the results ofÂsystematic reviews of therapeutic interventions. Journal of Clinical Epidemiology, 2015, 68, 1076-1084.	5.0	120
39	Law enforcement duties and sudden cardiac death among police officers in United States: case distribution study. BMJ, The, 2014, 349, g6534-g6534.	6.0	48
40	Opportunities and challenges in using studies without a control group in comparative effectiveness reviews. Research Synthesis Methods, 2014, 5, 152-161.	8.7	34
41	Can the Learning Health Care System Be Educated With Observational Data?. JAMA - Journal of the American Medical Association, 2014, 312, 129.	7.4	61
42	A Flexible, Multifaceted Approach Is Needed in Health Technology Assessment of PET. Journal of Nuclear Medicine, 2014, 55, 1225-1227.	5.0	5
43	Asymptomatic Carotid Artery Stenosis Treated with Medical Therapy Alone: Temporal Trends and Implications for Risk Assessment and the Design of Future Studies. Cerebrovascular Diseases, 2014, 38, 163-173.	1.7	57
44	Improving class probability estimates for imbalanced data. Knowledge and Information Systems, 2014, 41, 33-52.	3.2	39
45	Genotype Misclassification in Genetic Association Studies of the rs1042522 TP53 (Arg72Pro) Polymorphism: A Systematic Review of Studies of Breast, Lung, Colorectal, Ovarian, and Endometrial Cancer. American Journal of Epidemiology, 2013, 177, 1317-1325.	3.4	48
46	Survey of the methods and reporting practices in published metaâ€analyses of test performance: 1987 to 2009. Research Synthesis Methods, 2013, 4, 242-255.	8.7	9
47	Management Strategies for Asymptomatic Carotid Stenosis. Annals of Internal Medicine, 2013, 158, 676.	3.9	116